Document:

Exhibit

Exhibit 10.1

NEON THERAPEUTICS, INC.

AMENDED AND RESTATED NON-EMPLOYEE 
DIRECTOR COMPENSATION POLICY

The purpose of this amended and restated Non-Employee Director Compensation Policy of Neon Therapeutics, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries.  In furtherance of the purpose stated above, all non-employee directors shall be paid compensation for services provided to the Company as set forth below:

Cash Retainers

The Company shall pay cash retainers to the members of its Board of Directors (the “Board”) and the committees thereof as set forth below, such retainers to be (i) paid for the directors’ general availability and participation in meetings and conference calls, (ii) paid quarterly in arrears and (iii) pro-rated based on the number of actual days served by the director on the Board or applicable committee during such calendar quarter or year.
	
		
	Annual Retainer for Board Membership:
	$35,000

	Additional Annual Retainer for Non-Executive Chair of the Board:  
	$30,000

	Additional Retainers for Committee Membership:
	 

	Audit Committee Chair:
	$15,000

	Audit Committee Member:
	$7,500

	Compensation Committee Chair:
	$10,000

	Compensation Committee Member:
	$5,000

	Nominating and Corporate Governance Committee Chair:
	$8,000

	Nominating and Corporate Governance Committee Member:
	$4,000

Note: Chair and committee member retainers are in addition to retainers for members of the Board.

Each non-employee director may elect to receive all or a portion of her or his cash compensation in the form of unrestricted shares having a grant date fair value equal to the amount (or portion thereof) of such compensation.  Any such election (i) shall be made (x) for any continuing non-employee director, before the start of the calendar year with respect to any cash compensation for such calendar year and (y) for any new non-employee director, within 30 days of her or his election to the Board, (ii) shall be irrevocable with respect to such calendar year and (iii) shall automatically apply to the cash compensation for each subsequent calendar year unless otherwise revoked prior to the start of such calendar year.  

Equity Retainers

Initial Award: An initial, one-time equity award (the “Initial Award”) of a stock option to purchase 37,000 shares to each new non-employee director upon his or her election to the Board, which shall vest 33% on the first anniversary of the grant, then the remainder shall vest monthly for the subsequent two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Company.  This Initial Award applies only to non-employee directors who are first elected to the Board subsequent to the Company’s initial public offering.  Each Initial Award shall have a per share exercise price equal to the Fair Market Value (as defined in the Company’s 2018 Stock Option and Incentive Plan) of the Company’s common stock on the date of grant.
Annual Award:  On each date of the Company’s Annual Meeting of Stockholders following the completion of the Company’s initial public offering (the “Annual Meeting”), each continuing non-employee member of the Board, other than a director receiving an Initial Award, will receive an annual equity award (the “Annual Award”) of a stock option to purchase 18,500 shares, which shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.  Each Annual Award shall have a per share exercise price equal to the Fair Market Value (as defined in the Company’s 2018 Stock Option and Incentive Plan) of the Company’s common stock on the date of grant.

Expenses

The Company will reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board or any committee thereof.

*****
Adopted June 14, 2018, subject to effectiveness of the Company’s Registration Statement on Form S-1 for its initial public offering and reflecting the one-for-five reverse stock split effected on June 13, 2018.
Amended and restated on February 27, 2019.ofix-ex101_15.htm

Exhibit 10.1

 

 

July 30, 2019

 

 

Jon Serbousek

 

Offer Letter

 

Dear Jon,

 

It gives me great pleasure to present this offer of employment with Orthofix Medical, Inc. (with its subsidiaries and affiliates, “Orthofix”).  

 

Position:  The position we are offering you is that of President of Global Spine, reporting initially to Bradley Mason, Orthofix’s President and Chief Executive Officer.  Orthofix intends for you to remain in this position until Bradley Mason’s retirement, at which time Orthofix intends for you to assume the position of President and Chief Executive Officer, on terms commensurate with Orthofix’s overall executive compensation guiding principles.   

 

Start Date:  Your start date will be on August 5, 2019.

 

Base Salary:  Your base salary will be $500,000 per year (the “Base Salary”), less applicable deductions and tax withholdings.  

 

Annual Bonus:  Subject to Orthofix policies and satisfaction of applicable performance criteria, you will be eligible to participate in the annual bonus program, with a target bonus opportunity of 80% of your Base Salary.  Your 2019 annual bonus will be pro-rated based on your start date.   

 

Sign-On Equity Award:  As an inducement to and incentive for accepting this position, you will be eligible to receive a grant, effective as of your start date, of (i) stock options to purchase shares of Orthofix common stock, valued at $750,000 (based on the Black-Scholes value of Orthofix common stock on the grant date, subject to rounding to the nearest whole share) and (ii) restricted stock units with respect to shares of Orthofix common stock, valued at $750,000 (based on the closing price of Orthofix common stock on the grant date, subject to rounding to the nearest whole share), in each case vesting in 25% increments on each of the first four anniversaries of your start date, subject to your continued service with Orthofix on each such vesting date.  The sign-on equity awards are contingent upon and issued only upon approval by Orthofix’s Board of Directors and will be subject to the terms and conditions of applicable award agreements, which will be made available to you shortly after approval of your awards by Orthofix’s Board of Directors.  

 

Equity Incentives:  You will also be eligible to receive future, annual equity incentive awards.  Any future equity incentive awards are contingent upon and issued only upon 

Orthofix, Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000

www.orthofix.com

   

  

 

approval by Orthofix’s Board of Directors (or Compensation Committee) and will be subject to the terms and conditions of applicable plan documents and award agreements. 

 

Benefits:  Orthofix will offer you medical, dental, and vision insurance, effective the first of the month after your first 30 days of employment.  You will also be eligible to participate in the Orthofix 401(k) retirement plan as of the first of the month after your first 30 days of employment.  This plan currently provides an employer match of 100% for the first 2% contribution and 50% for the next 4% contribution.  A more detailed explanation of these benefits and other benefits will be provided to you under separate cover.  Orthofix defers to the provisions of its employee benefits plans, which plans shall govern to the extent of any conflict and which plans may be changed unilaterally by Orthofix.  

 

Location and Temporary Living Assistance:  Your position will be based in Orthofix’s Lewisville offices.  As such, Orthofix will provide support in establishing residency in the Lewisville, Texas area including reimbursement (upon submission of applicable supporting documentation) for 30 days temporary living, for weekly commuting costs to the Lewisville office beginning August 5 through November 1, 2019, and for closing costs on the purchase of a home.

  

Third-Party Confidentiality/Non-Compete Obligations:  Orthofix recognizes that, while you were employed with your prior employers, you may have been exposed to confidential, proprietary, and/or trade secret information (“Third-Party Confidential Information”).  Moreover, Orthofix recognizes that you have a legal duty and may have a contractual duty not to use or disclose Third-Party Confidential Information outside of your employment with your former employers.   Orthofix also recognizes that you may owe your former employers a contractual duty not to solicit certain customers (“Restricted Customers”).  Orthofix has no intention of obtaining any Third-Party Confidential Information in any form.  In fact, Orthofix’s expectation is that you will abide by, and comply fully with, the terms of any agreements you may have with respect to such information.  By signing below, you represent and warrant that you have complied, and will comply, with any such obligations, including, but not limited to, all confidentiality, non-solicitation, non-competition, and post-employment disclosure obligations.  You further represent and warrant that you have not misappropriated any Third-Party Confidential Information and, to the extent you may have access to such information, you will not disclose or use it for any purpose contrary to the terms of any agreements you may have with respect to such information, or to benefit Orthofix in any way.

 

Orthofix also wishes to ensure that you are not placed in a position which might require you to solicit Restricted Customers or cause the disclosure or use of Third-Party Confidential Information, either intentionally or inadvertently.  For this reason, this offer is contingent upon the legal department’s review of any agreements you may have with a current or former employer or business partner, and Orthofix reserves the right to rescind the offer if it determines, in its sole discretion, that you have continuing obligations to a current or former employer or business partner that could restrict or interfere with the responsibilities Orthofix anticipates you performing on its behalf.  If you are ever involved in any job situation which could require you to solicit Restricted Customers or cause you to use or disclose any Third-Party Confidential Information, you agree to immediately notify Orthofix’s Chief Legal 

Orthofix, Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000

www.orthofix.com

   

  

Exhibit 10.1

Officer and advise Orthofix’s Chief Legal Officer of your concerns.  In the event it is determined that a risk of improper solicitation, disclosure, or use does exist, Orthofix will take appropriate measures.

 

Orthofix is also serious about protecting its own confidential, proprietary, and/or trade secret information.  Accordingly, this offer of employment is contingent upon your execution of a confidentiality, non-competition, and inventions agreement (a “Restrictive Covenant Agreement”). 

 

Testing and Screening:  This offer is contingent on the successful completion of a drug test and background screening.  The drug screen must be completed within 48 hours of receipt of this offer letter.  If the drug screen is not completed by the designated date, we reserve the right to rescind the offer.    

 

Work Eligibility:  Federal law requires all employees to provide their employers with verification of identity and eligibility to work in the United States within the first three (3) days of employment.  All employees are required to show one or more forms of identification as a means of verification.  This offer of employment is contingent upon your return of the necessary documentation to Orthofix within three days of your first day of employment with a copy of the acceptable identification you choose to present.

 

Employment-At-Will:  You understand and acknowledge that, if you become employed by Orthofix, you will be an “at-will” employee at all times during your employment.  As an at-will employee, both Orthofix and you will have the right to terminate your employment at any time, with or without cause, and with or without notice.  At-will employment also means that your job duties, title, compensation, and benefits, as well as the company personnel policies and other procedures, may be changed or terminated at the sole discretion of Orthofix at any time.  Please note that, while this offer letter summarizes your anticipated terms and conditions of employment with Orthofix, they may change, and it is not an employment contract.  

 

Governing Law:  This offer letter shall be governed by and construed in accordance with the laws of the State of Texas, without regard to its principles of conflicts of laws.

 

Other Agreements:  Under separate cover, you will receive a Change in Control and Severance Agreement, an Indemnity Agreement, and a Restrictive Covenant Agreement (the “Other Agreements”).  Kindly return one signed copy of this offer letter and each Other Agreement.

 

Acceptance:  Your signature at the end of this offer letter constitutes an acceptance of this offer and confirms that no promises, representations, or agreements that are inconsistent with any of the terms of this offer letter have been made to or with you by anyone at Orthofix.  You also acknowledge and agree that no modification of the terms and conditions set forth in this offer letter can be made without the written authorization of Orthofix’s President and Chief Executive Officer or Orthofix’s Compensation Committee.

 

This offer of employment will remain open until August 1, 2019.

Orthofix, Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000

www.orthofix.com

   

  

 

 

Jon, we look forward to working with you.  Your experience, background and leadership will be a significant asset to Orthofix.  

 

 

Sincerely,

 

/s/ Ronald Matricaria

 

Ronald Matricaria

Chairman of the Board of Directors

 

 

 

 

 

 

ACKNOWLEDGED, ACCEPTED, AND AGREED:

 

 

 

/s/ Jon SerbousekDate July 31, 2019

Jon Serbousek

Orthofix, Inc. | 3451 Plano Parkway | Lewisville, TX 75056 | 214.937.2000

www.orthofix.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00298-of-00352.parquet"}]]